Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | JAK1 | P23458 | 1/20 | 0.61 |
| ▸ | TYK2 | P29597 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.61 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.61 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.54 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28822369 | 0.81 | ESR1 (0.65) | NPC1RAB9AMAPTSCN8ASCN10A | |
| SCHEMBL29571854 | 0.80 | ESR1 (0.68) | RAB9AMAPTKCNK3KCNK9SCN8A | |
| SCHEMBL16372042 | 0.80 | ESR1 (0.68) | RAB9AMAPTKCNK3KCNK9SCN8A | |
| SCHEMBL30777713 | 0.79 | SCN8A (0.59) | JAK2JAK1TYK2SCN8ASCN10A | |
| SCHEMBL17045005 | 0.78 | SCN8A (0.65) | NPC1RAB9AJAK2JAK1TYK2 | |
| SCHEMBL17045007 | 0.77 | SCN8A (0.65) | SCN8ASCN10A | |
| SCHEMBL31156451 | 0.76 | NPC1 (1.00) | NPC1RAB9AJAK2MAPT | |
| SCHEMBL4761937 | 0.76 | NPC1 (1.00) | NPC1RAB9AJAK2MAPT | |
| SCHEMBL17388978 | 0.76 | ROCK2 (0.64) | NPC1RAB9AMAPTHPGDMEN1 | |
| SCHEMBL2263696 | 0.76 | NPC1 (0.78) | NPC1RAB9AJAK2MAPTKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673864-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-10738009-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190248745-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2019-08-15 | — | — | US | disclosed |
| US-10087143-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180016235-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-01-18 | — | — | US | disclosed |
| US-9758483-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170037009-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2017-02-09 | — | — | US | disclosed |
| US-9393235-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2953931-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2015-12-16 | — | — | EP | disclosed |
| US-20150246028-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-09-03 | — | — | US | disclosed |
| US-9051270-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2014120808-A9 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PARMACEUTICALS INCORPORATED (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2014120808-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20140213616-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016235-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | NPC1 2284/4885RAB9A 3216/4885JAK2 2229/4885 |
| US-20150246028-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | NPC1 2284/4885RAB9A 3216/4885JAK2 2229/4885 |
| US-20140213616-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | NPC1 2284/4885RAB9A 3216/4885JAK2 2229/4885 |
| US-10738009-B2 | Pyridone amides as modulators of sodium channels | SCN5A, SCN1A, KCNJ2 | NPC1 2284/4885RAB9A 3216/4885JAK2 2229/4885 |
| US-20170037009-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | NPC1 2284/4885RAB9A 3216/4885JAK2 2229/4885 |
| US-11673864-B2 | Pyridone amides as modulators of sodium channels | SCN5A, SCN1A, KCNJ2 | NPC1 2284/4885RAB9A 3216/4885JAK2 2229/4885 |
| US-10087143-B2 | Pyridone amides as modulators of sodium channels | SCN5A, SCN1A, KCNJ2 | NPC1 2284/4885RAB9A 3216/4885JAK2 2229/4885 |
| US-20190248745-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | NPC1 2284/4885RAB9A 3216/4885JAK2 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.